Payment overview · 2025
General Payments
$384.67
22 reported records · 10 companies
Healthcare provider profile · identity verified
Timothy Blecha, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUPERIOR, NE · NPI 1790777936
Verified facts
What the public records show
CMS Open Payments records show Timothy Blecha, MD received $384.67 in general payments during 2025 across 22 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.38 | 17.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.00 | 15.3% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $53.61 | 13.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.22 | 11.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.72 | 11.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.10 | 9.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.08 | 9.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.06 | 4.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.94 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.56 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $384.67 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $102.46 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.00 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 183 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
126 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
183 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 734 | 153 |
| Montelukast Sodium | Montelukast Sodium | 667 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 618 | 110 |
| Spironolactone | Spironolactone | 527 | 86 |
| Losartan Potassium | Losartan Potassium | 509 | 92 |
| Famotidine | Famotidine | 475 | 75 |
| Gabapentin | Gabapentin | 441 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 393 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 61 |
| Metformin Hcl Er | Metformin Hcl | 312 | 58 |
| Furosemide | Furosemide | 310 | 60 |
| Omeprazole | Omeprazole | 297 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 225 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 221 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 219 | 43 |
| Memantine Hcl | Memantine Hcl | 204 | 32 |
| Tramadol Hcl | Tramadol Hcl | 203 | 46 |
| Eliquis | Apixaban | 197 | 33 |
| Jardiance | Empagliflozin | 197 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 38 |
| Sertraline Hcl | Sertraline Hcl | 190 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 189 | 23 |
| Lisinopril | Lisinopril | 188 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 35 |
| Ozempic | Semaglutide | 183 | 26 |
| Allopurinol | Allopurinol | 167 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 39 |
| Carvedilol | Carvedilol | 150 | 29 |
| Metformin Hcl | Metformin Hcl | 141 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 132 | 19 |
| Finasteride | Finasteride | 130 | 24 |
| Farxiga | Dapagliflozin Propanediol | 128 | 21 |
| Xarelto | Rivaroxaban | 126 | 15 |
| Glimepiride | Glimepiride | 122 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 41 |
| Bupropion Hcl Sr | Bupropion Hcl | 112 | 21 |
| Alprazolam | Alprazolam | 110 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 105 | 105 |
| Trazodone Hcl | Trazodone Hcl | 105 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 18 |
| Atenolol | Atenolol | 97 | 15 |
| Bupropion Xl | Bupropion Hcl | 97 | 17 |
| Potassium Chloride | Potassium Chloride | 95 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 95 | 22 |
| Valsartan | Valsartan | 93 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 11 |
| Meloxicam | Meloxicam | 91 | 28 |
| Donepezil Hcl | Donepezil Hcl | 89 | 13 |
| Fluconazole | Fluconazole | 89 | 34 |
| Warfarin Sodium | Warfarin Sodium | 89 | suppressed |
| Azithromycin | Azithromycin | 87 | 75 |
| Propranolol Hcl | Propranolol Hcl | 87 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 87 | 25 |
| Ezetimibe | Ezetimibe | 77 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 11 |
| Risperidone | Risperidone | 73 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 24 |
| Prednisone | Prednisone | 67 | 28 |
| Topiramate | Topiramate | 62 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 61 | suppressed |
| Clonazepam | Clonazepam | 58 | suppressed |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Mupirocin | Mupirocin | 53 | 34 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Loperamide | Loperamide Hcl | 45 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Letrozole | Letrozole | 44 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Sotalol | Sotalol Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | 17 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 40 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Testosterone | Testosterone | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Invokana | Canagliflozin | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 25 |
| Amoxicillin | Amoxicillin | 35 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 26 |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Acetazolamide | Acetazolamide | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 21 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Bethanechol Chloride | Bethanechol Chloride | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 16 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $384.67 · 22 records | Otsuka America Pharmaceutical, Inc. | CAPLYTA, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, MAVYRET, Ozempic, REXULTI, Rybelsus, SPRAVATO, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error